January 26th, 2026

The implementation of the Infarction Code prevented nearly 2,600 deaths in Catalonia during its first seven years

Deaths among patients with acute myocardial infarction before reaching hospital were reduced, during the response by the Medical Emergency System of Catalonia (SEM), by 20% during this period, compared with what would have been expected in the period prior to the implementation of this initiative. Overall, 28-day mortality after suffering a heart attack decreased significantly, falling from 27% of cases to 19%. These findings are highlighted in a study by researchers from the Hospital del Mar Research Institute, in collaboration with Hospital de Sant Pau and Hospital Clínic de Barcelona, which analysed data from 100,000 people who suffered a heart attack in Catalonia between 2008 and 2019.

Read more sobre "The implementation of the Infarction Code prevented nearly 2,600 deaths in Catalonia during its first seven years"

Researchers identify the role of senescent cells in breast cancer progression in preclinical models

Researchers from the Hospital del Mar Research Institute and the Vall d'Hebron Institute of Oncology have demonstrated, in animal models, the role played by these cells in the development of cancer cells. The study, published in Science Advances, shows that eliminating these cells at an early stage of tumor growth promotes tumor proliferation and the formation of metastases. By contrast, combining their elimination with an inhibitor of the CCL2 molecule reduces tumor size and eliminates metastases.

Read more sobre "Researchers identify the role of senescent cells in breast cancer progression in preclinical models"

December 16th, 2025

VIOLET Pharmaceuticals, the new spin-off of the Hospital del Mar Research Institute Barcelona, increases the effectiveness of immunotherapies for metastatic cancer

It aims to develop the first treatment based on mRNA therapy to boost the efficacy of immunotherapy for this type of tumour. The new company, a spin-off of the Hospital del Mar Research Institute Barcelona, plans to launch its first human clinical trial in 2028 to validate the safety of this approach. The project is led by Drs. Toni Celià-Terrassa and Joan Albanell, pioneers in the development of nanotherapies designed to transform tumours that are resistant to immunotherapy into tumours that are vulnerable to treatment.

Read more sobre "VIOLET Pharmaceuticals, the new spin-off of the Hospital del Mar Research Institute Barcelona, increases the effectiveness of immunotherapies for metastatic cancer"

MAR TECH TRANSFER ACADEMY: ¿Cómo captar financiación y pivotar en ciencias de la vida? SpliceBio, un caso de éxito

28 de enero de 2026

Recent Advances in Genitourinary Malignancies (RAGM-2026)

6 de febrero de 2026

Café GIPS - Hospital del Mar

3 de febrero de 2026